Optimal Antiplatelet and Lipid Therapy in ACS With DES: OPACT Trial

NCT07432516 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

4400

Enrollment

OTHER

Sponsor class

Conditions

Coronary Artery Disease

Interventions

DRUG: Discontinuation strategy + Combination lipid-lowering therapy
DRUG: Switching strategy + Combination lipid-lowering therapy
DRUG: Discontinuation strategy + High-intensity statin therapy
DRUG: Switching strategy + High-intensity statin therapy

Sponsor

Yonsei University